Drug metabolism and personalized therapy最新文献

{"title":"Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia.","authors":"Skokhrukh P Abdullaev, Maksim N Shatokhin, Svetlana N Tuchkova, Sherzod P Abdullaev, Oleg V Teodorovich, Oleg B Loran, Dmitry A Sychev","doi":"10.1515/dmpt-2023-0050","DOIUrl":"10.1515/dmpt-2023-0050","url":null,"abstract":"<p><strong>Objectives: </strong>Tamsulosin is a first-line drug for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Despite its high ratings for efficacy and safety, these parameters may vary due to genetic polymorphisms of CYP2D6 enzyme, which is involved in the metabolism of the drug. This variability may have great impact on the therapy of LUTS associated with BPH and may require an individualized approach to drug selection. The aim of the study was to assess the impact of genetic polymorphisms in CYP2D6 on the efficacy and safety of tamsulosin therapy in patients with LUTS associated with BPH.</p><p><strong>Methods: </strong>The study included 106 patients with LUTS/BPH (N40 according to ICD-10). All patients received monotherapy with tamsulosin 0.4 mg/day for at least 8 weeks. Depending on the severity of symptoms, all patients were divided into 2 groups based on the IPSS score: the first group of patients had moderate symptoms (n=57), and the second group of patients had severe symptoms (n=49). The results of treatment were assessed using the IPSS questionnaire with determination of quality of life (QoL), transrectal ultrasound of the prostate with determination of prostate volume and postvoid residual urine volume, and uroflowmetry. The carriage of allelic variants of CYP2D6 (*3, *4, *9, *10, and *41) were determined by polymerase chain reaction in all patients.</p><p><strong>Results: </strong>In patients with moderate symptoms who was classified as «intermediate» metabolizers by CYP2D6, a statistically significant greater reduction in symptoms according to the overall IPSS scale at 8 weeks (p=0.046) and the obstructive symptom subscale starting from 4 weeks of treatment (p<0.05) was shown. Allelic variants of the CYP2D6 gene did not affect the frequency of adverse reactions to tamsulosin.</p><p><strong>Conclusions: </strong>The results of the study show that in patients with moderate LUTS associated with BPH who are «intermediate» metabolizers by CYP2D6, there is a better therapeutic effect of tamsulosin.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"323-330"},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10127131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontmatter","authors":"","doi":"10.1515/dmpt-2023-frontmatter3","DOIUrl":"https://doi.org/10.1515/dmpt-2023-frontmatter3","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135299703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of personalized medicine for improving traditional medicine.","authors":"Ingrid Fricke-Galindo,&nbsp;Adrián LLerena","doi":"10.1515/dmdi-2023-0068","DOIUrl":"https://doi.org/10.1515/dmdi-2023-0068","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10407770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PDE5 inhibitors: breaking new grounds in the treatment of COVID-19.","authors":"Ryan Varghese, Gargi Digholkar, Jainam Karsiya, Sahil Salvi, Jeenam Shah, Dileep Kumar, Rohit Sharma","doi":"10.1515/dmpt-2023-0011","DOIUrl":"10.1515/dmpt-2023-0011","url":null,"abstract":"<p><strong>Introduction: </strong>Despite the ever-increasing occurrences of the coronavirus disease (COVID-19) cases around the world, very few medications have been validated in the clinical trials to combat COVID-19. Although several vaccines have been developed in the past quarter, the time elapsed between deployment and administration remains a major impediment.</p><p><strong>Content: </strong>Repurposing of pre-approved drugs, such as phosphodiesterase 5 (PDE5) inhibitors, could be a game-changer while lessening the burden on the current healthcare system. Repurposing and developing phosphodiesterase 5 (PDE5) inhibitors could extrapolate their utility to combat the SARS-CoV-2 infection, and potentially aid in the management of the symptoms associated with its newer variants such as BF.7, BQ.1, BQ.1.1, XBB.1.5, and XBB.1.16.</p><p><strong>Summary: </strong>Administration of PDE5 inhibitors via the oral and intravenous route demonstrates other potential off-label benefits, including anti-apoptotic, anti-inflammatory, antioxidant, and immunomodulatory effects, by intercepting several pathways. These effects can not only be of clinical importance in mild-to-moderate, but also moderate-to-severe SARS-CoV-2 infections. This article explores the various mechanisms by which PDE5 inhibitors alleviates the symptoms associated with COVID-19 as well as well as highlights recent studies and findings.</p><p><strong>Outlook: </strong>These benefits of PDE5 inhibitors make it a potential drug in the physicians' armamentarium in alleviating symptoms associated with SARS-CoV-2 infection. However, adequate clinical studies must be instituted to eliminate any untoward adverse events.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 4","pages":"295-307"},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PDE5 inhibitors: breaking new grounds in the treatment of COVID-19.","authors":"Ryan Varghese,&nbsp;Gargi Digholkar,&nbsp;Jainam Karsiya,&nbsp;Sahil Salvi,&nbsp;Jeenam Shah,&nbsp;Dileep Kumar,&nbsp;Rohit Sharma","doi":"10.1515/dmdi-2023-0011","DOIUrl":"https://doi.org/10.1515/dmdi-2023-0011","url":null,"abstract":"<p><strong>Introduction: </strong>Despite the ever-increasing occurrences of the coronavirus disease (COVID-19) cases around the world, very few medications have been validated in the clinical trials to combat COVID-19. Although several vaccines have been developed in the past quarter, the time elapsed between deployment and administration remains a major impediment.</p><p><strong>Content: </strong>Repurposing of pre-approved drugs, such as phosphodiesterase 5 (PDE5) inhibitors, could be a game-changer while lessening the burden on the current healthcare system. Repurposing and developing phosphodiesterase 5 (PDE5) inhibitors could extrapolate their utility to combat the SARS-CoV-2 infection, and potentially aid in the management of the symptoms associated with its newer variants such as BF.7, BQ.1, BQ.1.1, XBB.1.5, and XBB.1.16.</p><p><strong>Summary: </strong>Administration of PDE5 inhibitors via the oral and intravenous route demonstrates other potential off-label benefits, including anti-apoptotic, anti-inflammatory, antioxidant, and immunomodulatory effects, by intercepting several pathways. These effects can not only be of clinical importance in mild-to-moderate, but also moderate-to-severe SARS-CoV-2 infections. This article explores the various mechanisms by which PDE5 inhibitors alleviates the symptoms associated with COVID-19 as well as well as highlights recent studies and findings.</p><p><strong>Outlook: </strong>These benefits of PDE5 inhibitors make it a potential drug in the physicians' armamentarium in alleviating symptoms associated with SARS-CoV-2 infection. However, adequate clinical studies must be instituted to eliminate any untoward adverse events.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10052200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of personalized medicine for improving traditional medicine.","authors":"Ingrid Fricke-Galindo,&nbsp;Adrián LLerena","doi":"10.1515/dmpt-2023-0068","DOIUrl":"10.1515/dmpt-2023-0068","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 3","pages":"209-210"},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10286683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytochemical profiling and biological activities of <i>Diplazium esculentum</i> (Retz.) Sw.: an edible vegetable fern.","authors":"Kirti Raina, Alisha Chaudhary, Purnima Sharma, Rohit Sharma, Kanchan Bhardwaj, Pardeep Kumar, Atul Kabra, Sunil Thakur, Ashun Chaudhary, Mamta Prajapati, Pradeep Kumar Prajapati, Rajeev K Singla, Rohit Sharma","doi":"10.1515/dmpt-2023-0035","DOIUrl":"10.1515/dmpt-2023-0035","url":null,"abstract":"<p><strong>Objectives: </strong><i>Diplazium esculentum</i> (Retz.) Sw. is an edible vegetable fern of the Himalayan region with high nutritional and therapeutic value owing to its richness in various secondary metabolites and both macro and micronutrients.</p><p><strong>Content: </strong>This updated review discusses the general traditional use, ethnopharmacology, phytochemistry, nutritional value, pharmacology, and toxicity concerns of <i>D. esculentum.</i></p><p><strong>Summary: </strong>The plant parts, viz. rhizomes, shoots, fronds and leaves, have immense ethnomedicinal importance, being traditionally used to cure several health disorders. Among other pharmacological effects, this botanical reveals excellent anti-inflammatory, analgesic, antifungal, antibacterial, antioxidant, anti-leishmanial, antioxidant, anaphylactic, antipyretic, anthelmintic and hepatoprotective activities, directly attributed to the presence of many secondary metabolites. From a pharmacological point of view, the excellent antioxidant potential of <i>D. esculentum</i> suggests its promising use for nutraceutical or functional food formulation purposes.</p><p><strong>Outlook: </strong>Considering the evidences on popular ethnomedicinal uses of <i>D. esculentum</i> as an edible vegetable, its immense bio-potential, and multiple pharmacological roles, there is a huge need to evaluate its therapeutic applications in light of standard clinical trials.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"309-322"},"PeriodicalIF":0.0,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9924432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Kamini Vidrawan Ras</i> inducing opioid dependence? - understanding the facts.","authors":"Rohit Sharma, Ruchi Sharma, Subhadip Banerjee, Pradeep Kumar Prajapati","doi":"10.1515/dmpt-2023-0044","DOIUrl":"10.1515/dmpt-2023-0044","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"367-368"},"PeriodicalIF":0.0,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9927278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing.","authors":"Ekaterina Olegovna Golubenko, Marina Ivanovna Savelyeva, Zhannet Alimovna Sozaeva, Vera Vyacheslavovna Korennaya, Irina Vladimirovna Poddubnaya, Timur Tejmurazovich Valiev, Svetlana Nikolaevna Kondratenko, Mikhail Vitalyevich Ilyin","doi":"10.1515/dmpt-2023-0027","DOIUrl":"10.1515/dmpt-2023-0027","url":null,"abstract":"<p><strong>Objectives: </strong>The present study investigated the analysis of adverse drug reactions (ADRs) to tamoxifen (TAM) in breast cancer patients in relation to the carriage of genetic polymorphisms of genes encoding enzymes of CYP system and transporters of P-glycoprotein (Pg) and predictive models based on it.</p><p><strong>Methods: </strong>A total of 120 women with breast cancer taking adjuvant TAM were examined for the gene polymorphisms such as <i>CYP2D6*4</i>, <i>CYP3A5*3</i>, <i>CYP2C9*2</i>, <i>CYP2C9*3</i>, <i>CYP2C19*2</i>, <i>CYP2C19*3</i> and <i>ABCB1</i> (<i>C3435T</i>). Allelic variants were determined using the real-time polymerase chain reaction method. The research material was double sampling of buccal epithelium. Medical history data and extracts from case histories were used as sources of medical information, on the basis of which questionnaires specially created by us were filled out.</p><p><strong>Results: </strong>An associative analysis showed association with the development of ADRs to TAM indicating their clinical significance from different genetic polymorphisms of <i>CYP2D6</i>, <i>CYP3A5</i>, <i>CYP2C9</i> and <i>ABCB1</i>. The complex associative analysis performed using mathematical modeling made it possible to build predictive risk models for the development of ADRs such as hot flashes, dyspepsia, bone pain, and asthenia.</p><p><strong>Conclusions: </strong>Models that include both genetic and non-genetic determinants of ADRs of TAM may further improve the prediction of individual response to TAM.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"339-347"},"PeriodicalIF":0.0,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9829420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients.","authors":"Natalia P Denisenko,&nbsp;Anastasia A Kachanova,&nbsp;Ivan V Sychev,&nbsp;Gregory N Shuev,&nbsp;Oksana M Perfilieva,&nbsp;Reis H Mukhamadiev,&nbsp;Ruslan E Kazakov,&nbsp;Olga I Milyutina,&nbsp;Olga V Konenkova,&nbsp;Sergey A Ryzhkin,&nbsp;Elena M Zhmaeva,&nbsp;Sergey L Kirienko,&nbsp;Dmitriy V Ivashchenko,&nbsp;Irina V Bure,&nbsp;Alexander S Ametov,&nbsp;Irina V Poddubnaya,&nbsp;Karin B Mirzaev,&nbsp;Dmitry A Sychev","doi":"10.1515/dmdi-2023-0007","DOIUrl":"https://doi.org/10.1515/dmdi-2023-0007","url":null,"abstract":"<p><strong>Objectives: </strong>Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients.</p><p><strong>Methods: </strong>The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. <i>NFKB1</i>, <i>ATM</i>, <i>ATG16L2</i>, <i>ATG10</i>, <i>TGFB1</i>, and <i>TNF</i> polymorphisms were determined by allele-specific realtime-PCR.</p><p><strong>Results: </strong>The frequency of adverse reactions was the following: gastrointestinal symptoms - 57.9 %, local symptoms - 65.8 %, cerebral symptoms - 46.8 %, fatigue - 54.4 %; signs of sialoadenitis six months after radioiodine therapy - 25.2 %. TT genotype carriers of <i>ATG10</i> rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of <i>ATG10</i> rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of <i>TGFB1</i> rs1800469 (vs. AG+GG). CC genotype of <i>ATG10</i> rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the <i>ATM</i> rs11212570 had a protective role against fatigue. <i>TGFB1</i> rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy.</p><p><strong>Conclusions: </strong>Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9693793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}